Skip to content
DataLookout
Menu

PRESTONCT07938567

Preeclampsia Screening Trial to Improve Outcomes

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Pregnancy latency
Timeframe: At delivery (up to 40 weeks of gestation)
Participants with maternal adverse outcomes
Timeframe: From enrollment until post-natal discharge (on average 10 days post-delivery)

Secondary (8)

Number of participants who require hospital admission
Number of participants with indicated delivery within 14 days of presentation
Number of participants who require transfer to tertiary care centers
Number of participants who received antenatal corticosteroid administration
Number of preterm births less than 37 weeks
Show 3 moreShow less
Number of early preterm births
Composite Adverse Fetal/Neonatal Outcomes
Length of hospital admission (mother's) of stay,

Arms and interventions

Blinded Test Results (Phase A)Active comparator

Patients will be enrolled upon admission to the Labor \& Delivery/Maternity or antepartum units. Triage units will be considered part of Labor \& Delivery for this study. Management proceeds per local standard of care. Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes.

Real Time Results (Phase B)Experimental

Patients will be enrolled upon admission to the Labor \& Delivery/Maternity or antepartum units. Triage units will be considered part of Labor \& Delivery for this study. During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test.

Devices: Kryptor sFlt-1/PlGF assays on serum/plasma

Other: Treatment

Sites

1 site in 1 country

  • Emory Decatur HospitalDecatur, Georgia, United States